Rigel Pharmaceuticals Inc: Form 10-Q for the period ended Mar 31, 2021
Filed with the SEC on May 5, 2021 and accepted by EDGAR at May 5, 2021, 16:02 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2021-01-01 to 2021-03-31 | $81.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2021-01-01 to 2021-03-31 | $316.0k | us-gaap:CostOfGoodsAndServicesSold |
| Selling, general and administrative | 3 months2021-01-01 to 2021-03-31 | $22.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2021-01-01 to 2021-03-31 | $41.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2021-01-01 to 2021-03-31 | $485.0k | us-gaap:InterestExpense |
| Income tax | 3 months2021-01-01 to 2021-03-31 | $1.8m | us-gaap:IncomeTaxExpenseBenefit |
| Diluted EPS | 3 months2021-01-01 to 2021-03-31 | $0.22 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2021-01-01 to 2021-03-31 | $0.23 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2021-01-01 to 2021-03-31 | 176,069,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2021-01-01 to 2021-03-31 | −$20.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2021-01-01 to 2021-03-31 | $71.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2021-03-31 | $20.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-03-31 | $196.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-03-31 | $216.0m | us-gaap:Assets |
| Current liabilities | At period end2021-03-31 | $52.0m | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2021-03-31 | $20.0m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2021-03-31 | $78.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-21-005903. Last ingested by Listed: Nov 14, 2026, 23:09 ET. Listed shows no prices and gives no investment advice.